Ownership and insider activity for PDS Biotechnology Corporation (PDSB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer.
Price
| Price | $0.99 |
| Market Cap | $55M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-01-12 | BEDU-ADDO FRANK | A-Award | 548,782 | $538K |
| 2026-01-12 | CONN GREGORY | A-Award | 150,000 | $147K |
| 2026-01-12 | Shepard Kirk V. | A-Award | 300,000 | $294K |
| 2026-01-12 | Boesgaard Lars | A-Award | 300,000 | $294K |
| 2026-01-12 | Brown Spencer D. | A-Award | 300,000 | $294K |
| 2026-01-12 | Toutain Stephan | A-Award | 300,000 | $294K |
| 2026-01-12 | Freitag Gregory Gene | A-Award | 54,876 | $54K |
| 2026-01-12 | Iliev Ilian | A-Award | 54,876 | $54K |
| 2026-01-12 | Ali-Jackson Kamil | A-Award | 54,876 | $54K |
| 2026-01-12 | BRAWLEY OTIS W | A-Award | 54,876 | $54K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $106.4M | $88.1M | $34.6M | $12.2M | $28.8M | $65.2M | $73.8M | $56.6M | $41.7M | $26.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $107.4M | $89.1M | $35.7M | $14.5M | $30.3M | $66.8M | $76.5M | $59.1M | $45.1M | $28.3M |
| Property, Plant & Equipment | $3.4M | $3.4M | $426952 | $21051 | $553149 | $357697 | $527533 | $335005 | $304214 | $243698 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $51918 | $46805 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $110.9M | $92.6M | $36.2M | $14.5M | $30.9M | $67.2M | $77.0M | $59.4M | $45.4M | $30.5M |
| Accounts Payable | $3.5M | $4.4M | $399447 | $1.2M | $1.4M | $1.3M | $1.2M | $7.0M | $1.7M | $3.6M |
| Short-term Debt | 0 | $3.1M | 0 | 0 | 0 | 0 | 0 | $4.2M | $12.5M | $5.1M |
| Total Current Liabilities | $6.7M | $12.9M | $6.4M | $2.8M | $3.3M | $3.8M | $9.8M | $13.6M | $17.1M | $9.5M |
| Long-term Debt | $15.0M | $17.4M | $30000 | 0 | 0 | 0 | $23.0M | $19.5M | $9.2M | $11.7M |
| Total Liabilities | $21.6M | $30.2M | $6.4M | $2.8M | $3.8M | $4.0M | $33.0M | $33.3M | $26.4M | $21.2M |
| Retained Earnings | -$101.1M | -$151.9M | -$192.8M | -$28.9M | -$43.8M | -$60.7M | -$101.6M | -$144.5M | -$182.1M | -$216.6M |
| Total Equity | $89.3M | $62.4M | $29.8M | $11.7M | $27.1M | $63.2M | $44.0M | $26.1M | $19.0M | $9.3M |
| Total Debt | $15.0M | $20.5M | $30000 | 0 | $610257 | $490354 | $23.5M | $23.9M | $21.8M | $16.9M |
| Net Debt | -$91.4M | -$67.6M | -$34.6M | -$12.2M | -$28.2M | -$64.8M | -$50.3M | -$32.7M | -$19.9M | -$9.8M |
| Working Capital | $100.7M | $76.2M | $29.3M | $11.7M | $27.1M | $63.1M | $66.7M | $45.4M | $28.0M | $18.8M |
Financial Health
| Debt / Equity | -1.22 |
| Current Ratio | 0.57 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -11.61 |
Profitability
| Return on Equity | -708.20% |
| Return on Invested Capital | -3550.39% |
| Return on Assets | -382.32% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANVS · ATNM · FGEN · INMB · KZR · LVTX · OKUR
Explore sector: Healthcare · Biotechnology
More sections of PDSB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks